News & Press Releases
NEWS
Presentation of Saturn at NY Valves – June, 2026
At New York Valves 2026 InnovHeart brought three speakers: within the session "Innovations in TMVR", Dr. Paolo Denti from San Raffaele Hospital gave an overview of the Saturn Trans-septal TMVR System within the session "Mitral Interventions: TMVR with Novel Platforms...
Presentation of Saturn at CSI Frankfurt – June, 2026
Prof. Giedrius Davidavicius from VUL SK, Vilnius, presented the e-poster "Transseptal Transcatheter Mitral Valve replacement with a Saturn bioprosthesis" in the Structural and valvular interventions session at CSI Frankfurt on Thursday, Jun 4, 2026. Co-authors of the...
Presentation of Saturn at EuroPCR – May, 2026
Dr. Paolo Denti presented Saturn Trans-septal TMVR System and its first results in the European CASSINI study in the session "Registries and Trials in TMVR" at EuroPCR in Paris on Wednesday, May 20th, 2026. To quote Dr. Denti: "the Saturn TMVR System showed...
ENEA Tech e Biomedical and InnovHeart clinical development of Saturn TMVR system
Watch this video to learn more about the vision behind the Saturn TMVR from CEO David Wilson, Founder and CTO Giovanni Righini, and VP Quality Daniele Marziantonio. We are grateful to ENEA Tech e Biomedical for helping drive the clinical development of Saturn TMVR...
First Patient Results Published in JACC Case Reports
JACC Case Reports published the first report of a patient with the SATURN Trans-septal System in the CASSINI EU Early Feasibility Study. A 66-year-old woman with 3+ symptomatic MR patient underwent treatment with the fully percutaneous, transfemoral, transseptal...
PRESS RELEASES
First-In-Human Trans-Septal Implantation of Saturn Mitral Valve Replacement
We are pleased to announce the first trans-septal clinical trial implant with our proprietary Saturn Transcatheter Mitral Valve. Excellent hemodynamic results are reported for the patient, a 79 year old female suffering from severe mixed (degenerative and functional)...
InnovHeart appoints David Wilson as Chief Executive Officer
Industry Leader to Guide Company and the Saturn TMVR Programin its Next Phase of Growth InnovHeart s.r.l. announced today the appointment of David James Wilson, an experienced healthcare and medical device executive as Chief Executive Officer of the company and...
InnovHeart raises $55 million in Series C financing to further develop the Trans-septal Saturn Transcatheter Mitral Valve Replacement System
InnovHeart and Grand Pharmaceutical Group Enter Into an Exclusive License Agreement to Develop and Commercialize the Saturn TMVR Device in Greater China Milan, January 27, 2022 - InnovHeart s.r.l. announces the closing of its Series C financing with granting an...
Azin Parhizgar, Ph.D. Joins InnovHeart as Independent Member of the Board of Directors
InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of Mitral Regurgitation, announced today the appointment of successful serial entrepreneur and medical device executive Dr. Azin Parhizgar, Ph.D. as an...
InnovHeart Reports Successful First-in- Human Implantation of its Saturn Transcatheter Mitral Valve with Excellent 30-day Follow-up
InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of Mitral Regurgitation (MR), announced today the successful Firstin-Human implantation of its proprietary Saturn Transcatheter Mitral Valve along with...